Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Benitec Biopharma (BNTC) Shares Outstanding (Weighted Average) (2019 - 2025)

Benitec Biopharma has reported Shares Outstanding (Weighted Average) over the past 7 years, most recently at $46.0 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Weighted Average) at $46.0 million for Q4 2025, up 23.39% from a year ago — trailing twelve months through Dec 2025 was $46.0 million (up 23.39% YoY), and the annual figure for FY2025 was $36.2 million, up 97.17%.
  • Shares Outstanding (Weighted Average) reached $46.0 million in Q4 2025 per BNTC's latest filing, up from $20.4 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $46.0 million in Q4 2025 and bottomed at $6300.0 in Q2 2022.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $2.6 million (2023), compared with a mean of $13.1 million.
  • Peak annual rise in Shares Outstanding (Weighted Average) hit 39199.87% in 2022, while the deepest fall reached 99.85% in 2022.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $107095.0 in 2021, then soared by 1413.87% to $1.6 million in 2022, then soared by 58.91% to $2.6 million in 2023, then surged by 1346.03% to $37.3 million in 2024, then rose by 23.39% to $46.0 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for BNTC at $46.0 million in Q4 2025, $20.4 million in Q3 2025, and $36.2 million in Q2 2025.